Literature DB >> 16721854

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

Takeshi Ichinohe1, Izumi Watanabe, Eriko Tao, Satoshi Ito, Akira Kawaguchi, Shin-ichi Tamura, Hidehiro Takahashi, Hirofumi Sawa, Masami Moriyama, Joe Chiba, Katsuhiro Komase, Yujiro Suzuki, Takeshi Kurata, Tetsutaro Sata, Hideki Hasegawa.   

Abstract

A safe and effective adjuvant is necessary to enhance mucosal immune responses for the development of an inactivated intranasal influenza vaccine. The present study demonstrated the effectiveness of surf clam microparticles (SMP) derived from natural surf clams as an adjuvant for an intranasal influenza vaccine. The adjuvant effect of SMP was examined when co-administered intranasally with inactivated A/PR8 (H1N1) influenza virus hemagglutinin vaccine in BALB/c mice. Administration of the vaccine with SMP induced a high anti-PR8 haemagglutinin (HA)-specific immunoglobulin A (IgA) response in the nasal wash and immunoglobulin G (IgG) response in the serum, resulting in protection against both nasal-restricted infection and lethal lung infection by A/PR8 virus. In addition, administration of SMP with A/Yamagata (H1N1), A/Beijing (H1N1), or A/Guizhou (H3N2) vaccine conferred complete protection against A/PR8 virus challenge in the nasal infection model, suggesting that SMP adjuvanted vaccine can confer cross-protection against variant influenza viruses. The use of SMP is suggested as a new safe and effective mucosal adjuvant for nasal vaccination against influenza virus infection. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721854     DOI: 10.1002/jmv.20647

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Authors:  Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

2.  Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cells.

Authors:  Yong-Gang Li; Uamporn Siripanyaphinyo; Uranan Tumkosit; Nitchakarn Noranate; Atchareeya A-Nuegoonpipat; Yang Pan; Masanori Kameoka; Takeshi Kurosu; Kazuyoshi Ikuta; Naokazu Takeda; Surapee Anantapreecha
Journal:  Virol J       Date:  2012-06-14       Impact factor: 4.099

3.  Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia.

Authors:  Michael J Tuvim; Brian E Gilbert; Burton F Dickey; Scott E Evans
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

Review 4.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

5.  Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses.

Authors:  Heba M El Naggar; Mohamed Sayed Madkour; Hussein Ali Hussein
Journal:  Vet World       Date:  2017-02-14

6.  Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus.

Authors:  Norifumi Iijima; Melissa M Linehan; Melodie Zamora; Debbie Butkus; Robert Dunn; Marilyn R Kehry; Terri M Laufer; Akiko Iwasaki
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

7.  Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

Authors:  Hideki Hasegawa; Takeshi Ichinohe; Akira Ainai; Shin-Ichi Tamura; Takeshi Kurata
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

8.  [Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Authors:  F Denis; S Hantz; S Alain
Journal:  Antibiotiques (Paris)       Date:  2008-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.